Resistance Training to Prevent Lymphedema After Breast Cancer Surgery Randomized Controlled Study
Launched by YUE WANG · Jun 10, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • It was first diagnosed as grade I to III unilateral breast cancer by pathological examination； Breast cancer surgery was completed and axillary lymph node dissection was performed; To receive postoperative adjuvant treatment and follow-up in the outer fourth ward; Be able to communicate and exchange normally; Volunteer to participate in this research
- Exclusion Criteria:
- • Extreme fatigue, severe anemia, ataxia, etc.; The presence of upper limb or shoulder problems from breast cancer treatment; Edema is in a non-stable stage (stable stage of edema means no treatment for edema in the past 3 months; No inflammation of the upper extremities requiring anti-infective treatment; No change in daily activities; Limb circumference change \< 10%) ； Limited limb movement due to trauma, shoulder periarthritis, etc.; Limb braking is required for health reasons. Patients are lost to follow-up
About Yue Wang
Yue Wang is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous clinical studies. With a commitment to enhancing patient care and outcomes, Yue Wang collaborates with leading healthcare professionals and institutions to design and implement trials that adhere to the highest ethical and scientific standards. The organization emphasizes transparency, safety, and efficiency in its clinical operations, aiming to bring groundbreaking therapies and treatments to market while prioritizing the well-being of participants. Through its strategic partnerships and comprehensive approach, Yue Wang is poised to make significant contributions to the field of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported